Dr Beth Ann Griswold-Coller | Executive Director, Vaccines Clinical Research,
Merck Research Laboratories

Dr Beth Ann Griswold-Coller, Executive Director, Vaccines Clinical Research,, Merck Research Laboratories

Beth-Ann received her Ph.D. in 1993 from the University of Nebraska Medical Center, where she studied Medical Microbiology and Pathology, with a focus in virology. She then joined Hawaii Biotech Inc. where her efforts focused on development of viral vaccines based on recombinant subunit approaches. In 1999, Beth-Ann joined GlaxoSmithKline Biologicals in Rixensart, Belgium where she ultimately led the Preclinical Virology Group which was responsible for preclinical development of all viral vaccine projects, as well as serving as the project manager for the dengue vaccine project. In September 2004 Beth-Ann rejoined Hawaii Biotech and was given steadily increasing responsibilities, ultimately assuming the role of Senior Vice President for Research and Development, leading all research and development activities including advancing two products into clinical development.

In August 2010, Beth-Ann joined MRL as part of the Hawaii Biotech dengue program acquisition. She initially worked in the Vaccines Basic Research group supporting all aspects of the dengue vaccine program, as well as external collaborations across projects. In 2013 she transitioned to the Product Development Team (PDT) leader role. In the PDT leader role she has led the a number of different viral and bacterial vaccine programs. She is currently the PDT leader for the Ebola (V920) and dengue (V181) vaccine programs at Merck.

Appearances:



Day 2, September 29 @ 08:30

Introduction to Clinical Development and Trials Channel

Day 3, September 30th @ 14:10

The Ebola vaccine story; where are we now?

  • Wrapping up the DRC outbreak
  • The licensure process and unique pathway to regulatory approval
  • Policy & ethical considerations
  • Innovations, challenges and lessons learned throughout development
  • Implications for development of future emerging /re-emerging disease vaccines
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT
last published: 28/Sep/20 15:15 GMT

back to speakers